Avoro Capital, the deal killer behind the Seagen-Immunomedics blowup, has turned its eyes on Merck's Acceleron buyout

Kyle Blankenship

Merck’s proposed buyout of Acceleron Pharma represents a major bolt-on opportunity as the drugmaker looks to a future without megablockbuster Keytruda driving sales. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avoro Capital, the deal killer behind the Seagen-Immunomedics blowup, has turned its eyes on Merck's Acceleron buyout

Kyle Blankenship

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Avoro Cap­i­tal, the deal killer be­hind the Seagen-Im­munomedics blowup, has turned its eyes on Mer­ck­'s Ac­celeron buy­out

Kyle Blankenship

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

Avoro Capital, the deal killer behind the Seagen-Immunomedics blowup, has turned its eyes on Merck's Acceleron buyout

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Gilead buys experimental HIV vaccines from a small Barcelona biotech